Ravindra Mehrotra

Yatin Suneja

- Cyclerion Therapeutics, Inc. announced its **relaunch as a neuropsychiatric company** focused on developing therapies for conditions like treatment-resistant depression (TRD).  **[1755237_0001193125-25-213332_d51498dex991.htm:0]** 
- This transformation is underpinned by a **licensing agreement with the Massachusetts Institute of Technology (MIT)**, securing intellectual property for its lead program.  **[1755237_0001193125-25-213332_d51498dex991.htm:0]** **[1755237_0001193125-25-213332_d51498d8k.htm:1]** 
- The lead program, which targets TRD, is **Phase 2-ready**, with the initiation of a Phase 2 proof-of-concept trial expected in **2026** and initial data anticipated in **2027**.  **[1755237_0001193125-25-213332_d51498dex991.htm:0]**  
- Under the license agreement, MIT will receive a nominal upfront payment, up to **$4.4 million** in development, regulatory, and sales milestone payments, and tiered royalties in the low single digits based on future net sales of licensed products.  **[1755237_0001193125-25-213332_d51498d8k.htm:1]**

Cyclerion Therapeutics (CYCN)